Ra Capital Management, L.P. bought $30.0M of Mineralys Therapeutics (MLYS)
Executed Sep 4 2025, disclosed Sep 8 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 8 2025), the stock returned +9.1% (delay-adjusted); from the execution session (Sep 4 2025), +37.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→369,000 sh across 2 lots
Exec Mar 27
Filed Mar 31 · 4:15 PM ET